Castle Biosciences' TissueCypher Test Identifies High-Risk Barrett's…

Event summary

Castle Biosciences presented data from three studies at the ACG 2026 Annual Scientific Meeting showing TissueCypher can detect elevated risk of progression in Barrett's Esophagus beyond standard pathology findings.
TissueCypher identified high-risk cases in patients with non-dysplastic Barrett's Esophagus (NDBE), leading to earlier intervention and detection of previously missed dysplasia.
A multi-center study found TissueCypher changed management recommendations for 96% of patients, with 38 patients recommended for longer surveillance and 8 for endoscopic eradication therapy.
The test uses an AI-derived spatialomics approach to analyze protein biomarkers and tissue architecture in routine endoscopic biopsy samples.

The big picture

Castle Biosciences' TissueCypher test represents a strategic shift in Barrett's Esophagus management, moving from reliance on histopathology alone to incorporating molecular risk assessment. This aligns with broader trends in precision medicine, where molecular diagnostics are increasingly used to personalize patient care. The test's ability to identify high-risk cases missed by standard biopsies could significantly impact surveillance and treatment decisions, potentially reducing the progression to esophageal adenocarcinoma.

What we're watching

Clinical Adoption: Whether gastroenterologists will widely adopt TissueCypher for Barrett's Esophagus management, given its ability to provide additional risk information beyond standard pathology.
Reimbursement Dynamics: The pace at which payers will cover TissueCypher, which could impact its commercial success and market penetration.
Competitive Positioning: How Castle Biosciences will differentiate TissueCypher in a market where other molecular diagnostics for Barrett's Esophagus may emerge.